debrisoquin has been researched along with Dystonia in 1 studies
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
Dystonia: An attitude or posture due to the co-contraction of agonists and antagonist muscles in one region of the body. It most often affects the large axial muscles of the trunk and limb girdles. Conditions which feature persistent or recurrent episodes of dystonia as a primary manifestation of disease are referred to as DYSTONIC DISORDERS. (Adams et al., Principles of Neurology, 6th ed, p77)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the role of defective drug oxidation as a predisposing factor for neuroleptic-induced dystonic reactions, 26 patients who developed the reaction and 53 with no history of dystonia were phenotyped by the debrisoquine hydroxylation test." | 3.68 | Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions. ( Ancione, M; Caputi, AP; Di Rosa, AE; Meduri, M; Spina, E; Sturiale, V; Valvo, S, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Spina, E | 1 |
| Sturiale, V | 1 |
| Valvo, S | 1 |
| Ancione, M | 1 |
| Di Rosa, AE | 1 |
| Meduri, M | 1 |
| Caputi, AP | 1 |
1 other study available for debrisoquin and Dystonia
| Article | Year |
|---|---|
Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions.
Topics: Adult; Debrisoquin; Dystonia; Female; Humans; Male; Middle Aged; Oxidation-Reduction; Phenotype | 1992 |